에서 실시간으로 운영 중이에요! 자세히 알아보기
CYTK 아이콘

Cytokinetics

61.95 USD
-1.97
3.08%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
62.10
+0.15
0.24%
1일
-3.08%
5일
-0.85%
1개월
-10.72%
3개월
-22.91%
6개월
-5.3%
연초 이후
0.36%
1년
5.07%
5년
73.19%
10년
581.52%
 

소개: Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

직원 수: 673

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 31.3%
중립 65.6%
부정적 3.1%
중립
GlobeNewsWire
4일 전
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
중립
GlobeNewsWire
15일 전
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
중립
GlobeNewsWire
17일 전
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
긍정적
MarketBeat
21일 전
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
중립
GlobeNewsWire
29일 전
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
중립
Seeking Alpha
지난달
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
부정적
Seeking Alpha
지난달
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in the second quarter, despite competitive pressure from Bristol Myers Squibb's Camzyos. Meanwhile, the August 28 NEJM article revealed full Phase 3 ACACIA-HCM data, in which Myqorzo showed high efficacy in treating symptomatic nonobstructive HCM, where Camzyos failed.
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
중립
GlobeNewsWire
지난달
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
중립
Seeking Alpha
지난달
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
중립
GlobeNewsWire
지난달
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in September: Citi 2026 BioPharma Back to School Conference: Fireside chat on Wednesday, September 9, 2026 at 3:00 PM Eastern Time in New York, NY.
Cytokinetics to Participate in September Investor Conferences
Lightweight Charts™를 사용해 가격 차트를 구현했어요.